Fourrts offers a comprehensive range of products for asthma/allergy management with the purpose ‘To improve the lives of those living with Asthma & Allergies ’.
Fourrts has launched many first-time India products in asthma/allergy management, like L Montus, India’s first brand of levocetirizine and montelukast; Pulmoclear—a combination of acetylcysteine and acebrophylline in the management of COPD; and Allerbio—India’s first anti-allergic probiotic, which treats the root cause of allergy.
Currently our products have become an integral therapeutic tool in the management of COPD, Asthma & allergies.
India is facing a growing burden of chronic respiratory diseases like asthma and COPD, influenced by air pollution, urbanization, and health access gaps. Asthma affects 2–3.5% of adults, while COPD impacts 3–8%, with rural areas often affected by indoor pollution from biomass fuels.
In urban centers, outdoor air quality is a concern with elevated PM2.5 levels. Rising NO₂ and CO levels aggravate respiratory conditions, especially among vulnerable groups.
Addressing these challenges requires public awareness, improved diagnostic and treatment strategies, and stronger integration of respiratory care within primary healthcare systems.
Fourrts is committed to addressing this crisis with a comprehensive respiratory range that covers over 80% of respiratory conditions in India. As a pioneer in COPD, asthma, and allergy management, Fourrts has introduced several first-in-India products, setting new benchmarks in COPD, asthma, and allergy management, like L Montus, the world’s first levocetirizine and montelukast combination, and Pulmoclear another first-time-in-India combination of acetylcysteine and acebrophylline, which has transformed COPD management in India. Pulmoclear remains a trusted choice for pulmonologists; it was named Champion Brand of the Year in 2022 for its impact in respiratory care. Allerbio is India’s first anti-allergic probiotic, targeting allergies at the root cause.
We are leading a movement for better respiratory health. At Fourrts, our commitment is to continuous innovation—delivering effective, science-driven solutions that improve respiratory care and enhance patient outcomes.